Frankfurt
22.10.26 | 08:17
0,040 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08:39 | KLARIA PHARMA HOLDING AB: Klaria plans digital Q&A session with the company's CEO and chairman of the board | 1 | Cision News | ||
| Di | KLARIA PHARMA HOLDING AB: Klaria's chairman interviewed on the upcoming European launch of SAF and the potential in the U.S. | 1 | Cision News | ||
| Fr | Klaria Pharma Holding AB: Klaria Pharma: External valuation estimates peak sales for Sumatriptan Alginate Film at approx. USD 500 million per year | 359 | GlobeNewswire (Europe) | Klaria Pharma Holding AB (publ) ("Klaria" or the "Company") announces that the Company today publishes a summary of an external valuation of Klaria's leading project carried out by L.E.K Consulting.... ► Artikel lesen | |
| 14.10. | Listing Of Units Rights And Paid Subscription Units Of Klaria Pharma Holding AB | 357 | GlobeNewswire | With effect from October 15, 2026, the units rights in Klaria Pharma Holding AB will be traded on First North Growth Market. Trading will continue up until and including October 23, 2026.
... ► Artikel lesen | |
| 13.10. | KLARIA PHARMA HOLDING AB: KLARIA PHARMAISHES PROSPECTUS IN CONNECTION WITH RIGHTS ISSUE OF APPROXIMATELY SEK 147.6 MILLION | 3 | Cision News | ||
| 13.10. | Klaria Pharma Holding AB: Klaria Pharma Publishes Prospectus In Connection With Rights Issue Of Approximately Sek 147.6 Million | 169 | GlobeNewswire (Europe) | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE... ► Artikel lesen | |
| 08.10. | Klaria Pharma Holding AB: Klaria has secured subscription and underwriting commitments equivalent to approximately 75.3 percent of the rights offering, as well as bridge financing of approximately SEK 30.7 million | 184 | GlobeNewswire (Europe) | NOT FOR PUBLIC DISCLOSURE, PUBLICATION, OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND... ► Artikel lesen | |
| 08.10. | XFRA CAPITAL ADJUSTMENT INFORMATION - 08.10.2026 | 284 | Xetra Newsboard | Das Instrument 0PD0 GB00BSB7BS06 PINEWOOD TECH.GR. LS 1,0 EQUITY wird cum Kapitalmassnahme gehandelt am 08.10.2026 und ex Kapitalmassnahme am 09.10.2026 The instrument 0PD0 GB00BSB7BS06 PINEWOOD TECH.GR.... ► Artikel lesen | |
| KLARIA PHARMA Aktie jetzt für 0€ handeln | |||||
| 05.10. | Klaria Pharma Holding AB: Report from Extraordinary General Meeting of Klaria Pharma Holding AB (publ) | 191 | GlobeNewswire (Europe) | Today, an extraordinary general meeting was held in Klaria Pharma Holding AB (publ), reg.no. 556959-2917. Below is a summary of the resolutions adopted by the Extraordinary General Meeting (all in accordance... ► Artikel lesen | |
| 14.09. | KLARIA PHARMA HOLDING AB: Documents for the extraordinary general meeting will be available no later than September 21, 2026. | 2 | Cision News | ||
| 07.09. | Klaria Pharma Holding AB: Klaria and RTHS enter collaboration agreement for the development of early migraine detection and treatment | 190 | GlobeNewswire (Europe) | Klaria AB and Gothenburg-based RTHS have entered a collaboration agreement that aims to exploit RTHS sensor-based blood dynamics measurements to detect migraine prior to symptoms appearing in patients.... ► Artikel lesen | |
| 01.09. | Klaria Pharma Holding AB: Klaria Interim Report Q2 2026 | 179 | GlobeNewswire (Europe) | Summary of interim reportSecond quarter of 2026
The group in total
- Net sales 0.0 MSEK (0.0 MSEK)
- Other income 0.0 MSEK (0.0 MSEK)
- R&D expenses for the quarter amounted to 4.4 MSEK... ► Artikel lesen | |
| 01.09. | Summons to extraordinary general meeting of Klaria Pharma Holding AB (publ) | 1 | Cision News | ||
| 01.09. | Klaria Pharma Holding AB (publ) calls an Extraordinary General Meeting to resolve on a Rights Issue of units and an amendment of the Articles of Association | 1 | Cision News | ||
| 01.09. | Klaria Pharma Holding AB Q2 Loss Narrows | 1 | RTTNews | ||
| 26.08. | KLARIA PHARMA HOLDING AB: Klaria reschedules quarterly report date | 1 | Cision News | ||
| 07.08. | Klaria Pharma Holding AB: Klaria Receives EU Notification of Allowance for Sumatriptan Alginate Film | 745 | GlobeNewswire (Europe) | Klaria has received a Notice of Allowance from the European Patent Office for the second patent in the Sumatriptan Alginate Film (SAF) patent portfolio. The Notice of Allowance indicates that the second... ► Artikel lesen | |
| 26.06. | Klaria Pharma Holding AB: Report from the Annual General Meeting of Klaria Pharma Holding AB (publ) | 473 | GlobeNewswire (Europe) | Today, the Annual General Meeting 2026 of Klaria Pharma Holding AB (publ), reg. no. 556959-2917, was held. Below is a summary of the resolutions adopted by the Annual General Meeting (all in accordance... ► Artikel lesen | |
| 05.06. | KLARIA PHARMA HOLDING AB: Klaria Annual Report 2025 | 1 | Cision News | ||
| 05.06. | Klaria Pharma Holding AB: Klaria receives 25 MSEK in loan financing with the possibility of an additional 15 MSEK | 243 | GlobeNewswire (Europe) | Klaria Pharma Holding AB (publ) ("Klaria" or the "Company") announces that Klaria has entered into an agreement for a bridge loan of 25 MSEK from a Swedish finance company. The agreement also includes... ► Artikel lesen |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BRISTOL-MYERS SQUIBB | 54,89 | +0,81 % | Community Rückblick: BioNTech BNT113 Studie verfehlt Endpunkt: "Die Bude treibt einen zum Wahnsinn!" | © Foto: Julia Cebella - dpaBioNTech verfehlt mit BNT113 ein wichtiges Studienziel. Im wO-Forum streiten Anleger über die Zukunft der mRNA-Krebsforschung, die Bewertung der Aktie und das Potenzial der... ► Artikel lesen | |
| DERMAPHARM | 38,700 | -0,26 % | JEFFERIES stuft Dermapharm auf 'Hold' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Dermapharm nach einem Treffen mit dem Finanzchef Christof Dreibholz mit einem Kursziel von 44 Euro auf "Hold" belassen.... ► Artikel lesen | |
| INCYTE | 103,00 | +1,98 % | 17 Prozent Kursverlust nach Studienflop: Syndax stoppt Entwicklung - Mesoblast setzt auf den nächsten GvHD-Markt | ||
| GREEN THUMB INDUSTRIES | 5,720 | -1,89 % | President Trump's Push to Reschedule Marijuana Hit a Snag. Is Green Thumb Still a Buy? | ||
| COSMO | 57,20 | -0,35 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 19.10.2026 | Folgende Wertpapiere werden in den Handel an der Frankfurter Wertpapierbörse (FWB) aufgenommen.
1. US88025U1097 10X GENOMICS INC
2. NL0000852564 AALBERTS NV
3. SE0016589188 ELECTROLUX AB
4. SE0000115446... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 10,700 | -1,38 % | EILMELDUNG: Könnte die Aktie von SELLAS Life Sciences Group nach 15,0 % Plus jetzt komplett durchstarten? - Das dürfen Sie nicht verpassen! | ||
| OPKO HEALTH | 1,440 | +0,70 % | Labcorp To Acquire BioReference Health Assets; OPKO Shares Rise 7.35% | WASHINGTON (dpa-AFX) - Labcorp Holdings Inc. (LH), a provider of innovative and comprehensive laboratory services, on Thursday announced that it had agreed to acquire select assets of BioReference... ► Artikel lesen | |
| OXFORD BIOMEDICA | 6,150 | +0,82 % | OXB Appoints Joachim Kreuzburg as Independent Non-Executive Director | ||
| SUMITOMO PHARMA | 10,966 | +2,28 % | Sumitomo Pharma, Novo Nordisk Win Japan Nod For Wegovy In MASH | TOKYO (dpa-AFX) - Sumitomo Pharma Co., Ltd. (4506.T) announced on Friday that Japan has cleared Wegovy Subcutaneous Injection, which it co-promotes with Novo Nordisk B A/S (NVO), to treat metabolic... ► Artikel lesen | |
| CITIUS PHARMACEUTICALS | 0,398 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| VETOQUINOL | 77,50 | 0,00 % | Vetoquinol: 2026 Half Year Results | Sales: €259 million (+3.4% at constant exchange rates and +0.7% on a reported basis)
Essential Products sales: €169 million (+3.7% at constant exchange rates and +2.2% on a reported basis)
EBIT... ► Artikel lesen | |
| ASTRID INTELLIGENCE | 0,001 | 0,00 % | Astrid Intelligence - Green Compute Partnership and Operational Update | ||
| BIOHARVEST SCIENCES | 1,570 | 0,00 % | BioHarvest Sciences Inc.: BioHarvest Advances Proprietary Olive Cell Asset to Commercial Readiness, Opening New CDMO Licensing Opportunity | Botanical Synthesis-developed asset has now completed development, commercial-scale manufacturing and the applicable self-affirmed GRAS process and is ready for production at BioHarvest's GMP facilityMilestone... ► Artikel lesen | |
| OCUMENSION THERAPEUTICS | 0,492 | -1,20 % | OCUMENSION-B OT-101 Eye Drops Meet Primary Endpoint in Phase III Trial for Myopia Progression Delay | ||
| BAYER | 43,790 | -1,88 % | Bayer: Wird Nubeqa zum größten Medikament der Firmengeschichte? | Auf dem Krebskongress ESMO stehen Zwischendaten zu Bayers Prostatakrebsmittel Nubeqa an. Die BofA rechnet mit einem klaren Erfolg und traut dem Medikament den Rekord in der Konzerngeschichte zu. Bayer... ► Artikel lesen |
Das Unternehmen KLARIA PHARMA HOLDING AB kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,040 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KLARIA PHARMA HOLDING AB finden Sie auf Wallstreet Online.